In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster session 3: Atrial fibrillation: miscellaneous
Session

Event : ESC Congress 2014

Topic : Other

  • Session type : Poster Session
  • Date : 31 August 2014
  • Time : 14:00 - 18:00

13 presentations in this session

Discussant: Atrial fibrillation: miscelaned.

Event : ESC Congress 2014

  • Session : Atrial fibrillation: miscellaneous

Familial clustering and subsequent incidence of atrial fibrillation among first-degree relatives in Denmark

Event : ESC Congress 2014

  • Session : Atrial fibrillation: miscellaneous
  • Speaker : E Fosbol (Kbh O,DK)

High physical fitness; associated with increased or reduced atrial fibrillation risk in middle-aged men?

Event : ESC Congress 2014

  • Session : Atrial fibrillation: miscellaneous
  • Speaker : I Grundvold (Oslo,NO)

Formation and resolution of left atrial thrombus during dabigatran therapy: a JHRS survey report

Event : ESC Congress 2014

  • Session : Atrial fibrillation: miscellaneous
  • Speaker : H Mitamura (Tokyo,JP)

Plasma vWF levels are involved in AF development in ischaemic patients undergoing cardiac surgery

Event : ESC Congress 2014

  • Session : Atrial fibrillation: miscellaneous
  • Speaker : D Hernandez Romero (El Palmar,ES)

Predictors for new-onset post-operative atrial fibrillation in patients undergoing aortic valve replacement

Event : ESC Congress 2014

  • Session : Atrial fibrillation: miscellaneous
  • Speaker : L Iliuta (Bucharest,RO)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are